ClinicalTrials.gg

TargetBeta

KRAS

KRas proto-oncogene, GTPase · also KRAS1, K-Ras4B, KRAS2 · RAS type GTPase family

41 programs in company-led studies act on KRAS, from 32 companies: 16 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (31 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 31211 running–NCIt
daraxonrasibruleRevolution Medicinesphase 31010 runningHRAS, NRASNCIt
divarasibHoffmann-La Rochephase 3139 running–a judged reading
calderasibMerckphase 3128 running–a judged reading
glecirasibruleAllist Pharmaceuticalsphase 3128 running–NCIt
adagrasibruleBristol-Myers Squibbphase 3167 running–NCIt
olomorasibEli Lillyphase 3167 running–a judged reading
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 377 running–the company's pipeline
sotorasibruleAmgenphase 3286 running–NCIt
HRS-7058Jiangsu HengRui Medicinephase 366 running–the company's pipeline
zoldonrasibruleRevolution Medicinesphase 366 running–NCIt
garsorasibruleInventisBiophase 384 running–NCIt
KRAS G12D Inhibitor INCB161734ruleIncytephase 354 running–NCIt
opnurasibruleNovartisphase 353 running–NCIt
KRAS G12C Inhibitor JMKX001899ruleJemincarephase 333 running–NCIt
KRAS G12C Inhibitor HS-10370ruleHansoh Pharmaceutical Groupphase 321 running–NCIt
KRAS G12D Inhibitor QLC1101ruleQilu Pharmaceuticalphase 233 running–NCIt
Pan-KRAS Inhibitor JAB-23E73Jacobio Pharmaceuticalsphase 222 running–a judged reading
elisrasibruleD3 Bio (Wuxi)phase 221 running–NCIt
Pan-KRAS Inhibitor BLU-924Sanofiphase 211 running–the company's pipeline
KRAS G12D Inhibitor KQB548ruleBayerphase 122 running–NCIt
AZD0240AstraZenecaphase 111 running–a judged reading
HS-10529ruleHansoh Pharmaceutical Groupphase 111 running–the studies' text
HS-10541Hansoh Pharmaceutical Groupphase 111 running–the company's pipeline
KRAS G12D Inhibitor INCB186748ruleIncytephase 111 running–NCIt
KRAS G12V Inhibitor RMC-5127ruleRevolution Medicinesphase 111 running–NCIt
KRAS Mutant Inhibitor ALTA3263ruleAlterome Therapeuticsphase 111 running–NCIt
KRAS Mutant Inhibitor BBO-11818ruleTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)phase 111 running–NCIt
KRAS Mutant Inhibitor KQB365ruleKumquat Biosciencesphase 111 running–NCIt
KRAS Mutant Inhibitor KQB368ruleKumquat Biosciencesphase 111 running–NCIt
KRAS Mutant Inhibitor QTX3544ruleQuanta Therapeuticsphase 111 running–NCIt
LT-010391ruleLeadingtac Pharmaceutical (Shaoxing)phase 111 running–the studies' text
NW-301VruleNeowise Biotechnologyphase 111 running–the studies' text
Pan-KRAS Degrader ASP5834ruleAstellas Pharmaphase 111 running–NCIt
Pan-KRAS Degrader PT0511rulePAQ Therapeuticsphase 111 running–NCIt
Pan-KRAS Inhibitor AMG 410ruleAmgenphase 111 running–NCIt
Pan-KRAS Inhibitor AUBE00Hoffmann-La Rochephase 111 running–the company's pipeline
Pan-KRAS Inhibitor ERAS-4001ruleErascaphase 111 running–NCIt
Pan-KRAS Inhibitor TLN-372ruleTreeline Biosciencesphase 111 running–NCIt
RAS Inhibitor AN9025ruleAdlai Nortye Biopharmaphase 111 runningNRASNCIt
Pan-KRAS Inhibitor PF-07985045rulePfizerphase 110 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.